Otsuka

Abilify Asimtufii campaign uses 3D CGI to detail journey of bipolar I patients
Medical Marketing and Media
Mon, 09/9/24 - 07:14 pm
pharma marketing
DTC advertising
Ability Asimtufii
Otsuka
Lundbeck
Otsuka Pays Up to $1.1B to Buy Jnana, Adds Drug Discovery Capabilities
BioSpace
Thu, 08/1/24 - 11:26 am
Otsuka
M&A
Jnana Therapeutics
drug discovery
Why Otsuka launched a digital health company
Medical Marketing and Media
Mon, 06/10/24 - 11:13 am
Otsuka
Otsuka Precision Health
Medtech
digital therapeutics
major depressive disorder
Otsuka defies digital health downturn with new company
BioPharma Dive
Thu, 05/30/24 - 11:07 am
Otsuka
Medtech
digital health
major depressive disorder
Otsuka Precision Health
Otsuka and Lundbeck report data from three PTSD treatment trials
Clinical Trials Arena
Wed, 05/29/24 - 11:52 am
Otsuka
Lundbeck
PTSD
clinical tirals
brexpiprazole-sertraline
Otsuka Drops Alzheimer’s Agitation Drug Following Phase III Failure
BioSpace
Wed, 05/22/24 - 11:20 am
Otsuka
Alzheimer's disease
Alzheimer's agitation
clinical trials
AVP-786
3 patent expirations in 2024 and how companies are pivoting
Pharma Voice
Wed, 04/17/24 - 11:13 am
patents
patent cliff
Bayer
J&J
Xarelto
Novo Nordisk
Victoza
Otsuka
Lundbeck
Abilify
Otsuka Drug Candidate Fails Phase III Alzheimer’s Agitation Study
BioSpace
Tue, 02/13/24 - 11:27 am
Otsuka
clinical trials
AVP-786
Alzheimer's agitation
FDA rules Otsuka marketing claim overstates Rexulti efficacy, threatening cornerstone of huge TV push
Fierce Pharma
Tue, 11/14/23 - 11:19 am
Otsuka
FDA
Rexulti
pharma marketing
clinical depression
Otsuka reports positive data from two Phase III ADHD treatment trials
Clinical Trials Arena
Mon, 10/30/23 - 11:44 am
Otsuka
clinical trials
ADHD
centanafadine
Otsuka, Shape Ink Potential $1.5B Deal to Develop Eye AAV Gene Therapies
BioSpace
Fri, 09/8/23 - 10:11 am
Otsuka
Shape Therapeutics
gene therapy
AAV gene therapy
RNA editing
ocular diseases
Evaluating renal denervation rivals, FDA advisory panel backs ReCor, shuns Medtronic
Fierce Biotech
Fri, 08/25/23 - 09:51 am
Medtech
FDA
renal denervation
Otsuka
Recor
Medtronic
hypertension
Sumitomo, Otsuka’s Schizophrenia Candidate Fails Phase III Trials
BioSpace
Mon, 07/31/23 - 09:50 pm
Sumitomo Pharma
Otsuka
clinical trials
ulotaront
schizophrenia
Hope springs for April inhibition
EP Vantage
Tue, 06/13/23 - 10:27 am
Novartis
Chinook Therapeutics
April inhibition
M&A
Vera Therapeutics
Otsuka
RemeGen
Alpine Immune Sciences
Akso Biopharmaceutical
Aurinia Pharmaceuticals
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Yahoo/Benzinga
Thu, 05/11/23 - 08:53 pm
Otsuka
Lundbeck
FDA
Rexulti
Alzheimer's agitation
Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify
Fierce Pharma
Mon, 05/1/23 - 10:04 am
Otsuka
Lundbeck
FDA
Abilify
Asimtufii
bipolar disorder
Sunovion, Otsuka randomize first patient for GAD Phase II/III study
Clinical Trials Arena
Thu, 04/27/23 - 10:27 am
Sunovion
Otsuka
clinicat trials
ulotaront
generalized anxiety disorder
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation
Fierce Pharma
Sun, 04/16/23 - 11:17 pm
Lundbeck
Otsuka
Rexulti
Alzheimer's disease
FDA
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Otsuka, Lundbeck eye Alzheimer's indication in FDA adcomm for Rexulti label expansion
Endpoints
Thu, 03/30/23 - 10:02 am
Otsuka
Lundbeck
Alzheimer's disease
FDA
Rexulti
Alzheimer's disease agitation

Pages